文献速递淋巴瘤造血干细胞移植与细胞治疗

塔法西他单抗占据CD19可提高CART19细胞疗法的治疗指数并减轻细胞因子释放综合征的严重程度

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
PubMed 文献 · Blood · 2024-01-01

在临床前模型中评估CD19单抗塔法西他单抗与CART19联合时的相互干扰。同时给药出现CD19结合竞争并损害CART19功能;但CD19+细胞系经塔法西他单抗过夜预处理并去除游离抗体后,CART19功能未受影响。体内模型中,塔法西他单抗预处理较单用CART19降低了细胞因子释放综合征的发生率和严重程度,并表现出更优的抗肿瘤效果和总生存,与短暂的CD19占据抑制CART19过度活化、减少CAR T细胞凋亡和肿瘤细胞焦亡相关。

要点

  • 同时给予塔法西他单抗与CART19存在主要CD19结合竞争,导致CART19功能受损。
  • CD19+细胞系经塔法西他单抗过夜预处理并去除游离抗体后,CART19功能未受影响。
  • 体内模型中塔法西他单抗预处理较单用CART19降低细胞因子释放综合征发生率和严重程度,抗肿瘤效果和总生存更优。

核心结论

  • 临床前模型中,塔法西他单抗预处理通过短暂占据CD19抑制CART19过度活化,降低细胞因子释放综合征发生率和严重程度,并较单用CART19表现出更优的抗肿瘤效果和总生存。

研究设计与样本

  • 临床前研究,在体外细胞系和体内模型中评估CD19单抗塔法西他单抗与CART19治疗的相互干扰。

主要发现

  • 同时给予塔法西他单抗与CART19出现主要CD19结合竞争,导致CART19功能受损。
  • CD19+细胞系经塔法西他单抗过夜预处理并去除未结合抗体后,CART19功能未受影响。
  • 体内模型中,塔法西他单抗预处理较单用CART19降低了细胞因子释放综合征的发生率和严重程度,并表现出更优的抗肿瘤效果和总生存。
  • 上述效应与塔法西他单抗短暂占据CD19相关,进而抑制CART19过度活化,减少CAR T细胞凋亡和肿瘤细胞焦亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the development of various strategies of anti-CD19 immunotherapy for the treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal antibody therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19) therapy. We evaluated the potential interference between the CD19-targeting monoclonal antibody tafasitamab and CART19 treatment in preclinical models. Concomitant treatment with tafasitamab and CART19 showed major CD19 binding competition, which led to CART19 functional impairment. However, when CD19+ cell lines were pretreated with tafasitamab overnight and the unbound antibody was subsequently removed from the culture, CART19 function was not affected. In preclinical in vivo models, tafasitamab pretreatment demonstrated reduced incidence and severity of cytokine release syndrome and exhibited superior antitumor effects and overall survival compared with CART19 alone. This was associated with transient CD19 occupancy with tafasitamab, which in turn resulted in the inhibition of CART19 overactivation, leading to diminished CAR T apoptosis and pyroptosis of tumor cells.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sakemura RL, Manriquez Roman C, Horvei P, et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024. PMID: 37879074. doi:10.1182/blood.2022018905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。